English

• 14 Oct, 2025
  Visible tumor uptake and recommended dose increase in Spago Nanomedicals’s Phase I/IIa study Tumorad-01
• 20 Aug, 2025
  Spago Nanomedical interim report January-June, 2025
• 3 Jun, 2025
  Spago Nanomedical continues patient recruitment in the phase I/IIa study Tumorad-01 as planned after DMC recommendation
• 14 May, 2025
  Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB
• 7 May, 2025
  Spago Nanomedical interim report January-March, 2025
• 15 Apr, 2025
  Spago Nanomedical publishes the annual report for 2024
• 9 Apr, 2025
  NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL)
• 20 Mar, 2025
  Nomination committee’s proposal for a new chairman and composition of Spago Nanomedical’s board
• 4 Mar, 2025
  Spago Nanomedical proceeds with increased dose in the phase I/IIa study Tumorad-01
• 6 Feb, 2025
  Spago Nanomedical year-end report January-December, 2024